Biogen Inc (BIIB)

303.96
14.00 5.00
NASDAQ : Health Care
Prev Close 289.54
Open 305.24
Day Low/High 300.51 / 305.82
52 Wk Low/High 223.02 / 338.51
Volume 463.64K
Avg Volume 1.55M
Exchange NASDAQ
Shares Outstanding 217.57M
Market Cap 62.07B
EPS 15.40
P/E Ratio 19.38
Div & Yield N.A. (N.A)

Latest News

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Biogen Shares Spike on Leaked Alzheimer's Drug Data

Shares are Biogen spiked on the aducanumab data leak as investors with unfair access to what was supposed to be embargoed results traded on the information.

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.

Http://www.sobi.com

Http://www.sobi.com

Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the...

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

C, AAPL, FB: Jim Cramer's Views

C, AAPL, FB: Jim Cramer's Views

Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Biogen Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 23, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Biogen Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 23, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial

Based on the negative study results, Lilly will not pursue regulatory approvals for solanezumab in Alzheimer's disease.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

The bullish side dominates, with consumer cyclicals and energy names most prevalent.

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

BIIB SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Shareholders Of A Class Action Involving Biogen Inc. And A Lead Plaintiff Deadline Of December 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Biogen Announces Additional Members Of Management Team Of Hemophilia Spin-off Company Bioverativ

Biogen Announces Additional Members Of Management Team Of Hemophilia Spin-off Company Bioverativ

Biogen (NASDAQ: BIIB) today announced the addition of two members to the executive management team of Bioverativ Inc.

Stocks Surge After Trump Victory

Stocks Surge After Trump Victory

Stocks close at session highs on Wednesday as the idea of a Trump presidency settles in. Financial and health care sectors lead the market.

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks post solid gains Wednesday after plunging overnight following Donald Trump's surprising victory in the U.S. presidential race.

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

Midday Report: Stocks Higher As Wall Street Shrugs Off Trump's Presidential Election

U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.

Stocks Turn Positive After Trump's Surprising Election Win

Stocks Turn Positive After Trump's Surprising Election Win

Stocks turn positive Wednesday as investors gauge a Donald Trump presidency on markets. Drug, biotech and financial stocks jump.

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.

Stock Futures Remain Sharply Lower Following Trump's Victory

Stock Futures Remain Sharply Lower Following Trump's Victory

Stock futures fall on Wednesday as voters elect Donald Trump as the next U.S. president.

Biogen Sees Positive Drug Study Results

Biogen Sees Positive Drug Study Results

Shares of Biogen were higher on Monday after the biotech company and Ionis Pharmaceuticals said their Phase 3 trial of its spinal muscular atrophy drug met its primary endpoint.

Biogen (BIIB) Upgraded to 'Buy' at Piper, Analysts Weigh In

Biogen (BIIB) Upgraded to 'Buy' at Piper, Analysts Weigh In

Ritholtz Wealth Management CEO Josh Brown and Lebenthal Asset Management CEO Jim Lebenthal believe Biogen's (BIIB) valuation is too cheap.

Shares of Biogen, Ionis Gain on Positive Spinraza Trial

Shares of Biogen, Ionis Gain on Positive Spinraza Trial

Shares of Biogen and Ionis are rallying on positive results from a late-stage trial of Spinraza.

Hang On for Biogen

Hang On for Biogen

Biogen's rough ride may not be over yet, but investors could make money if they hang on.

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.

Biogen And Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint At Interim Analysis Of Phase 3 CHERISH Study In Later-Onset Spinal Muscular Atrophy

Biogen And Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint At Interim Analysis Of Phase 3 CHERISH Study In Later-Onset Spinal Muscular Atrophy

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that SPINRAZA TM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of...